Elanix Biotechnologies AG (FRA:ELN) Net Income From Continuing Operations : €-3.73 Mil (TTM As of Dec. 2018)

View and export this data going back to . Start your Free Trial

What is Elanix Biotechnologies AG Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Elanix Biotechnologies AG's net income from continuing operations for the six months ended in Dec. 2018 was €-1.08 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2018 was €-3.73 Mil.

Elanix Biotechnologies AG Net Income From Continuing Operations Historical Data

The historical data trend for Elanix Biotechnologies AG's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elanix Biotechnologies AG Net Income From Continuing Operations Chart

Elanix Biotechnologies AG Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Net Income From Continuing Operations

Get a 7-Day Free Trial

-0.02

-2.79

-1.89

-3.00

-3.73

Elanix Biotechnologies AG Semi-Annual Data
	Dec08	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18
Net Income From Continuing Operations	Get a 7-Day Free Trial															-1.11	-1.68	-1.32	-2.65	-1.08

Elanix Biotechnologies AG Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2018 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-3.73 Mil.

Elanix Biotechnologies AG (FRA:ELN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Elanix Biotechnologies AG (FRA:ELN) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

Street-4, Georg-Glock, c/o HEUKING KÜHN LÜER WOJTEK, Dusseldorf, NW, DEU, 40474

Website

https://www.elanixbiotechnologies.ch

Elanix Biotechnologies AG is a tissue regeneration company. It develops and commercializes products for acute wound care, dermatological and gynecological applications as well as providing cell technology services. The company's operating segment include Regenerative Medicine and Cosmetic ointments. It generates maximum revenue from the Cosmetic ointments segment. Geographically, it derives a majority of revenue from Switzerland and also has a presence in the EU, and Taiwan.

Elanix Biotechnologies AG (FRA:ELN) Headlines

No Headlines